{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:38:53Z","timestamp":1779367133801,"version":"3.53.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.prdoa.2025.100307","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:28:13Z","timestamp":1739820493000},"page":"100307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative safety of istradefylline in Parkinson\u2019s disease: A systematic review of randomized controlled trials and real-world studies"],"prefix":"10.1016","volume":"12","author":[{"given":"Sagari","family":"Bett\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-1576","authenticated-orcid":false,"given":"Joyce","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Batson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Redhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hodkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prdoa.2025.100307_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.prdoa.2025.100307_b0010","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.prdoa.2025.100307_b0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor complications of dopaminergic medications in Parkinson\u2019s disease","volume":"37","author":"Freitas","year":"2017","journal-title":"Semin. Neurol."},{"issue":"1","key":"10.1016\/j.prdoa.2025.100307_b0020","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: a mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.prdoa.2025.100307_b0025","unstructured":"J. Choi, K.A. Horner. Dopamine Agonists, StatPearls PublishingUpdated 26 Jun 2023."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100307_b0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","article-title":"Pooled analyses of Phase III studies of ADS-5102 (Amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Elmer","year":"2018","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.prdoa.2025.100307_b0035","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson\u2019s disease","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.prdoa.2025.100307_b0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/PPA.S11182","article-title":"Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson\u2019s disease","volume":"5","author":"Robottom","year":"2011","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.prdoa.2025.100307_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.prdoa.2025.100307_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signalling"},{"issue":"4","key":"10.1016\/j.prdoa.2025.100307_b0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","article-title":"Adenosine A2A receptors in Parkinson\u2019s disease treatment","volume":"4","author":"Cie\u015blak","year":"2008","journal-title":"Purinergic Signal."},{"issue":"1","key":"10.1016\/j.prdoa.2025.100307_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000331768","article-title":"Adenosine A2A-receptor antagonism and pathophysiology of Parkinson\u2019s disease and drug-induced movement disorders","volume":"67","author":"Kulisevsky","year":"2011","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.prdoa.2025.100307_b0065","doi-asserted-by":"crossref","unstructured":"A. Mori, Chapter Four - Mode of Action of Adenosine A2A Receptor Antagonists as Symptomatic Treatment for Parkinson\u2019s Disease, in: A. Mori (Ed.), International Review of Neurobiology, Academic Press2014, pp. 87-116.","DOI":"10.1016\/B978-0-12-801022-8.00004-0"},{"issue":"27","key":"10.1016\/j.prdoa.2025.100307_b0070","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1523\/JNEUROSCI.6730-10.2011","article-title":"Arousal effect of caffeine depends on adenosine A<sub>2A<\/sub> receptors in the shell of the nucleus accumbens","volume":"31","author":"Lazarus","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.prdoa.2025.100307_b0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2017.07.045","article-title":"Istradefylline improves daytime sleepiness in patients with Parkinson\u2019s disease: an open-label, 3-month study","volume":"380","author":"Suzuki","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100307_b0080","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3233\/JPD-212672","article-title":"Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson\u2019s disease: a pooled analysis of 8 Phase 2b\/3 trials","volume":"11","author":"Hauser","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100307_b0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.23517","article-title":"Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson\u2019s disease","volume":"26","author":"Stowe","year":"2011","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2025.100307_b0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","article-title":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease - network meta-analysis","volume":"9","author":"Sako","year":"2023","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"10.1016\/j.prdoa.2025.100307_b0095","unstructured":"Y. Torres-Yaghi, J. Qian, H. Cummings, H. Shimoda, S. Ito, S. Batson, S. Mitchell, F. Pagan, Comparative safety of istradefylline among Parkinson\u2019s disease adjunctive therapies: a systematic review and meta-analysis of randomized controlled studies, Clin. Neuropharmacol. (in press)."},{"key":"10.1016\/j.prdoa.2025.100307_b0100","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.prdoa.2025.100307_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.prdoa.2025.100307_b0110","unstructured":"S. Dias, N.J. Welton, A.J. Sutton, A.E. Ades. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, www.nicedsu.org.uk (2011)."},{"key":"10.1016\/j.prdoa.2025.100307_b0115","unstructured":"S. Dias, N.J. Welton, A.J. Sutton, D.M. Valdwell, L. Guobing, A.E. Ades. NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials, www.nicedsu.org.uk (2011)."},{"key":"10.1016\/j.prdoa.2025.100307_b0120","unstructured":"S. Dias, N.J. Welton, A.J. Sutton, D.M. Valdwell, L. Guobing, A.E. Ades. NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment., www.nicedsu.org.uk (2011)."},{"issue":"980","key":"10.1016\/j.prdoa.2025.100307_b0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.prdoa.2025.100307_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120619","article-title":"Risk factors for developing dyskinesia among Parkinson\u2019s disease patients with wearing-off: J-FIRST","volume":"448","author":"Mishima","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100307_b0135","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jrsm.1085","article-title":"Assessing key assumptions of network meta-analysis: a review of methods","volume":"4","author":"Donegan","year":"2013","journal-title":"Res. Synth. Methods"},{"issue":"26","key":"10.1016\/j.prdoa.2025.100307_b0140","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou","year":"2022","journal-title":"Stat. Med."}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:18:35Z","timestamp":1775819915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112525000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"alternative-id":["S2590112525000118"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100307","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of istradefylline in Parkinson\u2019s disease: A systematic review of randomized controlled trials and real-world studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100307"}}